Cargando…

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2

Detalles Bibliográficos
Autores principales:	Caffo, O., Zagonel, V., Baldessari, C., Berruti, A., Bortolus, R., Buti, S., Ceresoli, G.L., Donini, M., Ermacora, P., Fornarini, G., Fratino, L., Masini, C., Massari, F., Mosca, A., Mucciarini, C., Procopio, G., Tucci, M., Verri, E., Zucali, P., Buttigliero, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299865/ https://www.ncbi.nlm.nih.gov/pubmed/32562741 http://dx.doi.org/10.1016/j.annonc.2020.06.005

Ejemplares similares

Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer
por: Caffo, Orazio, et al.
Publicado: (2020)

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
por: Fornarini, G., et al.
Publicado: (2021)

GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak
por: Bersanelli, Melissa, et al.
Publicado: (2021)

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
por: Buti, Sebastiano, et al.
Publicado: (2021)

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
por: Rebuzzi, S.E., et al.
Publicado: (2022)

The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
por: Basso, Umberto, et al.
Publicado: (2022)

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
por: Fiorica, Francesco, et al.
Publicado: (2022)

Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network
por: Rescigno, Pasquale, et al.
Publicado: (2022)

Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways
por: Bungaro, Maristella, et al.
Publicado: (2020)

An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study
por: Internò, V., et al.
Publicado: (2023)

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
por: Turco, Fabio, et al.
Publicado: (2022)

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
por: Catalano, Martina, et al.
Publicado: (2023)

Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice
por: Mazziotti, Gherardo, et al.
Publicado: (2022)

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
por: Stellato, Marco, et al.
Publicado: (2021)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
por: Stellato, Marco, et al.
Publicado: (2023)

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease
por: Berruti, A, et al.
Publicado: (2005)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
por: Santoni, Matteo, et al.
Publicado: (2019)

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
por: Iuliani, Michele, et al.
Publicado: (2015)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic
por: Fratino, Lucia, et al.
Publicado: (2020)

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
por: Procopio, Giuseppe, et al.
Publicado: (2022)

Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
por: Ceresoli, G L, et al.
Publicado: (2014)

Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review
por: Marandino, Laura, et al.
Publicado: (2020)

Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
por: Canova, S., et al.
Publicado: (2022)

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
por: Mark, M., et al.
Publicado: (2022)

Deprivation, discrimination, human rights violation, and mental health of the deprived
por: Jiloha, R. C.
Publicado: (2010)

LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study
por: Bersanelli, M., et al.
Publicado: (2020)

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
por: Maruzzo, Marco, et al.
Publicado: (2021)

Does deprivation affect breast cancer management?
por: Henley, N C, et al.
Publicado: (2005)

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
por: Zichi, Clizia, et al.
Publicado: (2017)

Electrophoresis in nanochannels: brief review and speculation
por: Baldessari, Fabio, et al.
Publicado: (2006)

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rhfl2v508msck1h5b43rd0g820